Raptiva®
Manufacturer: Genetech
Uses: Treatment of psoriasis.
More Information
On April 8, 2009, Genetech, the manufacturer of the
psoriasis drug Raptiva announced that it is voluntarily
withdrawing Raptiva from the United States market.
According to the FDA, Genetech is withdrawing Raptiva
because of a potential risk to patients in developing
progressive multifocal leukoencephalopathy (PML), a rare
serious progressive neurological disease caused by a
virus that attacks the central nervous system. On
June 8, 2009, Raptiva will no longer be available in the
United States.
The risk that an individual patient taking Raptiva
will develop multifocal leukoencephalopathy (PML) is
rare and generally associated with long-term use.
There is no known effective treatment for PML.
What is Raptiva
Raptiva is a once weekly injection for
adults with moderate to severe plaque psoriasis.
It was approved by the Food and Drug Administration in
2003. Raptiva has also been linked to:
If you or someone you know suffered any of the above
injuries or symptoms, please either click below for a
free case evaluation, or call us at 877-Drug Giant
(877-378-4442), 816-Law Firm (816-529-3476), or
816-531-4440.
|
